Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Chronic lymphocytic leukemia (CLL) is tough. There always seems to be some new mutations and more things that go wrong that we need to understand to best plan our treatment for
At ASH 2016 Dr. George Follows of Cambridge, England discusses our evolving understanding of life after ibrutinib for those of us with CLL. Richter’s transformation tends to occur early on and may be a reflection of the heavy treatment many patients had received before starting ibrutinib in the early trials and is not part of this interview.
By Nancy O’Brien Simpson – Patient The year was 2005, and I was a psychotherapist who had the world by the tail. A gorgeous family, an amazing home, a stellar career,
Why the Patient’s Perspective is So Important Part 1: Whom am I? I was asked by friends to help with a campaign to ensure that the voice of informed patients be heard more loudly, more clearly and more often at large medical congresses such as ASH (American Society
Here is a helpful link from the American Cancer Society that explains the differences between Phase I, II, III and IV trials. While the party line is that Phase I trials
One click to our most popular content.
